GSK (NYSE:GSK) Upgraded to “Strong-Buy” at StockNews.com

GSK (NYSE:GSK) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Other analysts also recently issued reports about the company. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE:GSK opened at $34.08 on Friday. The firm has a 50 day simple moving average of $35.16 and a 200 day simple moving average of $38.68. The company has a market cap of $70.63 billion, a price-to-earnings ratio of 22.13, a PEG ratio of 1.54 and a beta of 0.64. GSK has a one year low of $32.83 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

Institutional Investors Weigh In On GSK

A number of large investors have recently bought and sold shares of GSK. Bank of New York Mellon Corp grew its stake in shares of GSK by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 926,517 shares of the pharmaceutical company’s stock valued at $35,671,000 after buying an additional 69,649 shares during the period. Crossmark Global Holdings Inc. boosted its holdings in GSK by 2.7% in the second quarter. Crossmark Global Holdings Inc. now owns 30,543 shares of the pharmaceutical company’s stock worth $1,176,000 after acquiring an additional 803 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in GSK by 6.3% in the second quarter. International Assets Investment Management LLC now owns 5,535 shares of the pharmaceutical company’s stock worth $213,000 after acquiring an additional 327 shares in the last quarter. Hantz Financial Services Inc. acquired a new stake in GSK in the second quarter valued at approximately $3,032,000. Finally, Rothschild Investment LLC bought a new stake in shares of GSK during the second quarter valued at approximately $688,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.